Ipsen (IPN.PA) Announces Acceptance Of Filings For Somatuline® In The Treatment Of GEP-NET1s In The U.S. With Priority Review And In Europe
9/2/2014 12:03:26 PM
PARIS--(BUSINESS WIRE)--Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review of its supplemental New Drug Application (sNDA) for Somatuline® Depot® 120mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The FDA designates priority review status to drug candidates that have the potential to offer a significant improvement in treatment compared to currently approved options. Decision is expected in early Q1, 2015.
Help employers find you! Check out all the jobs and post your resume.
comments powered by